La cadena de opciones muestra datos clave de las opciones de acciones de Grifols a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Grifols..

Grifols (NASDAQ:GRFS) Bolsa, Cadena de Opciones

Grifols

Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.

GRFS

Kintbury Capital y Millennium reabren cortos en Grifols antes de sus resultados del 4 de noviembre, aumentando la expectativa de volatilidad.

Grifols enfrenta sus resultados con presión bajista y alta volatilidad prevista

Los resultados apuntan a un trimestre estable, con mejora operativa, reducción de deuda y avances que refuerzan la confianza inversora.

Grifols mejora márgenes y caja pese al tipo de cambio: foco en dividendo y deuda

Rovi Laboratorios

ALMRY

MRNA

Jefferies ha reiterado su recomendación de compra sobre Laboratorios Farmacéuticos Rovi (BME:ROVI) tras reunirse con su director financiero (CFO). El interés del banco se apoya en tres palancas operativas y en un marco de objetivos a 2030 que prioriza crecimiento rentable y diversificación.

Acciones de Rovi (ROVI) reciben respaldo de Jefferies con potencial superior al 20 %

Grifols, S.A. - American Depositary Shares

Grifols SA

Health Care

Press Releases

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Mason Capital Management Highlights Corporate Governance Failures and Significant Shareholder Value Destruction Under Grifols Board of Directors

Mason Capital Reiterates Corporate Governance Shortcomings and Mismanagement of Grifols Under Current Board of Directors

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson's Disease

Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

Abivax

Arcellx

Alkermes

Arrowhead Pharmaceuticals, Inc. - Common Stock

Arrowhead Pharma

BioMarin Pharmaceutical Inc. - Common Stock

BioMarin Pharmaceutical

Caris Life Sciences

CRISPR Therapeutics

Cytokinetics, Incorporated - Common Stock

Cytokinetics

Exelixis

Halozyme Therapeutics, Inc. - Common Stock

Halozyme Therapeutics

Krystal Biotech

Kymera Therapeutics

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Madrigal Pharmaceuticals, Inc. - Common Stock

Madrigal Pharmaceuticals

Moderna

Merus

Metsera

Nuvalent

Vaxcyte

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

PTC Therapeutics

Protagonist Therapeutics, Inc. - Common Stock

Protagonist Therapeutics

Avidity Biosciences

Rhythm Pharmaceuticals, Inc. - Common Stock

Comments

Grifols

Grifols (GRFS) Opciones

Grifols (NASDAQ:GRFS) Bolsa, Cadena de Opciones

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL